Phase 5: Global Rollout & Institutional Adoption (Mid–Late 2026)
Objective: Expand DeMedic across borders and into clinical workflows.
Key Milestones:
Enterprise researcher plans and access licenses
Integration with EHR platforms and genomic testing services
Multilingual platform support and region-specific interfaces
DAO-curated grants for rare disease data collection
Launch of white-label platform for patient groups, NGOs, and nonprofits
Strategic partnerships with global health initiatives (WHO, academic alliances)
Last updated